vs

Side-by-side financial comparison of Lineage Cell Therapeutics, Inc. (LCTX) and MOVING iMAGE TECHNOLOGIES INC. (MITQ). Click either name above to swap in a different company.

Lineage Cell Therapeutics, Inc. is the larger business by last-quarter revenue ($6.6M vs $3.8M, roughly 1.7× MOVING iMAGE TECHNOLOGIES INC.). Lineage Cell Therapeutics, Inc. runs the higher net margin — 12.9% vs -10.2%, a 23.1% gap on every dollar of revenue. On growth, Lineage Cell Therapeutics, Inc. posted the faster year-over-year revenue change (130.4% vs 10.2%). Over the past eight quarters, Lineage Cell Therapeutics, Inc.'s revenue compounded faster (113.9% CAGR vs 7.8%).

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to eithe...

Silicon Image Inc. was an American fabless semiconductor company based in Hillsboro, Oregon, and active from 1995 to 2015. The company designed circuits for mobile phones, consumer electronics and personal computers (PCs). It also manufactured wireless and wired connectivity products used for high-definition content. The company's semiconductor and IP products were deployed by manufacturers in devices such as smartphones, tablets, digital televisions (DTVs), and other consumer electronics, as...

LCTX vs MITQ — Head-to-Head

Bigger by revenue
LCTX
LCTX
1.7× larger
LCTX
$6.6M
$3.8M
MITQ
Growing faster (revenue YoY)
LCTX
LCTX
+120.2% gap
LCTX
130.4%
10.2%
MITQ
Higher net margin
LCTX
LCTX
23.1% more per $
LCTX
12.9%
-10.2%
MITQ
Faster 2-yr revenue CAGR
LCTX
LCTX
Annualised
LCTX
113.9%
7.8%
MITQ

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
LCTX
LCTX
MITQ
MITQ
Revenue
$6.6M
$3.8M
Net Profit
$851.0K
$-388.0K
Gross Margin
30.7%
Operating Margin
-99.1%
-10.8%
Net Margin
12.9%
-10.2%
Revenue YoY
130.4%
10.2%
Net Profit YoY
126.0%
26.4%
EPS (diluted)
$0.00
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LCTX
LCTX
MITQ
MITQ
Q4 25
$6.6M
$3.8M
Q3 25
$3.7M
$5.6M
Q2 25
$2.8M
Q1 25
$1.5M
$3.6M
Q4 24
$2.9M
$3.4M
Q3 24
$3.8M
$5.3M
Q2 24
$1.4M
$6.3M
Q1 24
$1.4M
$3.9M
Net Profit
LCTX
LCTX
MITQ
MITQ
Q4 25
$851.0K
$-388.0K
Q3 25
$-29.8M
$509.0K
Q2 25
$-30.5M
Q1 25
$-4.1M
$-240.0K
Q4 24
$-3.3M
$-527.0K
Q3 24
$-3.0M
$-25.0K
Q2 24
$-5.8M
$-416.0K
Q1 24
$-6.5M
$-601.0K
Gross Margin
LCTX
LCTX
MITQ
MITQ
Q4 25
30.7%
Q3 25
30.0%
Q2 25
Q1 25
97.6%
29.8%
Q4 24
94.6%
27.2%
Q3 24
99.0%
26.1%
Q2 24
96.9%
22.5%
Q1 24
93.2%
17.4%
Operating Margin
LCTX
LCTX
MITQ
MITQ
Q4 25
-99.1%
-10.8%
Q3 25
-102.9%
6.3%
Q2 25
-715.4%
Q1 25
-433.1%
-7.6%
Q4 24
-178.2%
-16.3%
Q3 24
-101.6%
-1.3%
Q2 24
-416.7%
-7.3%
Q1 24
-461.3%
-16.7%
Net Margin
LCTX
LCTX
MITQ
MITQ
Q4 25
12.9%
-10.2%
Q3 25
-809.0%
9.1%
Q2 25
-1101.8%
Q1 25
-275.6%
-6.7%
Q4 24
-114.1%
-15.3%
Q3 24
-80.3%
-0.5%
Q2 24
-409.1%
-6.6%
Q1 24
-453.0%
-15.4%
EPS (diluted)
LCTX
LCTX
MITQ
MITQ
Q4 25
$0.00
$-0.04
Q3 25
$-0.13
$0.05
Q2 25
$-0.13
Q1 25
$-0.02
$-0.02
Q4 24
$0.00
$-0.05
Q3 24
$-0.02
$0.00
Q2 24
$-0.03
$-0.04
Q1 24
$-0.04
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LCTX
LCTX
MITQ
MITQ
Cash + ST InvestmentsLiquidity on hand
$55.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$44.5M
$5.0M
Total Assets
$112.6M
$9.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LCTX
LCTX
MITQ
MITQ
Q4 25
$55.8M
Q3 25
$40.5M
Q2 25
$42.3M
Q1 25
$47.9M
Q4 24
$47.8M
Q3 24
$32.7M
Q2 24
$38.5M
Q1 24
$43.6M
Stockholders' Equity
LCTX
LCTX
MITQ
MITQ
Q4 25
$44.5M
$5.0M
Q3 25
$22.0M
$5.4M
Q2 25
$48.4M
Q1 25
$79.0M
$5.0M
Q4 24
$78.4M
$5.2M
Q3 24
$66.2M
$5.7M
Q2 24
$68.3M
$5.7M
Q1 24
$72.4M
$6.3M
Total Assets
LCTX
LCTX
MITQ
MITQ
Q4 25
$112.6M
$9.5M
Q3 25
$89.6M
$11.3M
Q2 25
$90.8M
Q1 25
$111.8M
$11.2M
Q4 24
$113.2M
$10.0M
Q3 24
$96.6M
$10.7M
Q2 24
$102.8M
$10.5M
Q1 24
$108.5M
$12.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LCTX
LCTX
MITQ
MITQ
Operating Cash FlowLast quarter
$-4.9M
$-1.6M
Free Cash FlowOCF − Capex
$-5.3M
FCF MarginFCF / Revenue
-79.9%
Capex IntensityCapex / Revenue
6.0%
Cash ConversionOCF / Net Profit
-5.73×
TTM Free Cash FlowTrailing 4 quarters
$-19.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LCTX
LCTX
MITQ
MITQ
Q4 25
$-4.9M
$-1.6M
Q3 25
$-3.6M
$-167.0K
Q2 25
$-5.5M
Q1 25
$-4.9M
$53.0K
Q4 24
$-6.3M
$70.0K
Q3 24
$-5.8M
$-32.0K
Q2 24
$-5.2M
$-472.0K
Q1 24
$-5.8M
$1.0M
Free Cash Flow
LCTX
LCTX
MITQ
MITQ
Q4 25
$-5.3M
Q3 25
$-3.6M
Q2 25
$-5.6M
Q1 25
$-5.0M
Q4 24
$-6.7M
Q3 24
$-5.9M
Q2 24
$-5.2M
Q1 24
$-5.8M
FCF Margin
LCTX
LCTX
MITQ
MITQ
Q4 25
-79.9%
Q3 25
-98.6%
Q2 25
-200.8%
Q1 25
-331.8%
Q4 24
-234.0%
Q3 24
-156.1%
Q2 24
-371.2%
Q1 24
-403.1%
Capex Intensity
LCTX
LCTX
MITQ
MITQ
Q4 25
6.0%
Q3 25
0.3%
Q2 25
0.5%
Q1 25
6.5%
Q4 24
12.7%
Q3 24
3.0%
Q2 24
3.6%
0.0%
Q1 24
2.6%
0.0%
Cash Conversion
LCTX
LCTX
MITQ
MITQ
Q4 25
-5.73×
Q3 25
-0.33×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LCTX
LCTX

Collaboration Revenues$6.3M95%
Other$345.0K5%

MITQ
MITQ

Segment breakdown not available.

Related Comparisons